Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial - PubMed (original) (raw)
Clinical Trial
Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial
G Bleichner et al. Intensive Care Med. 1997 May.
Abstract
Objective: To assess the preventive effect of Saccharomyces boulardii on diarrhea in critically ill tube-fed patients and to evaluate risk factors for diarrhea.
Design: Prospective, multicenter, randomized, double-blind placebo-controlled study.
Setting: Eleven intensive care units in teaching and general hospitals.
Patients: Critically ill patients whose need for enteral nutrition was expected to exceed 6 days.
Intervention: S. boulardii 500 mg four times a day versus placebo.
Measurements and results: Diarrhea was defined by a semiquantitative score based on the volume and consistency of stools. A total of 128 patients were studied, 64 in each group. Treatment with S. boulardii reduced the mean percentage of days with diarrhea per feeding days from 18.9 to 14.2% [odds ratio (OR) = 0.67, 95% confidence interval (CI) = 0.50-0.90, P = 0.0069]. In the control group, nine risk factors were significantly associated with diarrhea: nonsterile administration of nutrients in open containers, previous suspension of oral feeding, malnutrition, hypoalbuminemia, sepsis syndrome, multiple organ failure, presence of an infection site, fever or hypothermia, and use of antibiotics. Five independent factors were associated with diarrhea in a multivariate analysis: fever or hypothermia, malnutrition, hypoalbuminemia, previous suspension of oral feeding, and presence of an infection site. After adjustment for these factors, the preventive effect of S. boulardii on diarrhea was even more significant (OR = 0.61, 95% CI = 0.44-0.84, P < 0.0023).
Conclusions: S. boulardii prevents diarrhea in critically ill tube-fed patients, especially in patients with risk factors for diarrhea.
Similar articles
- Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial.
Pozzoni P, Riva A, Bellatorre AG, Amigoni M, Redaelli E, Ronchetti A, Stefani M, Tironi R, Molteni EE, Conte D, Casazza G, Colli A. Pozzoni P, et al. Am J Gastroenterol. 2012 Jun;107(6):922-31. doi: 10.1038/ajg.2012.56. Epub 2012 Apr 3. Am J Gastroenterol. 2012. PMID: 22472744 Clinical Trial. - [A multicenter randomized controlled study of Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in infants and young children].
Wan CM, Yu H, Liu G, Xu HM, Mao ZQ, Xu Y, Jin Y, Luo RP, Wang WJ, Fang F. Wan CM, et al. Zhonghua Er Ke Za Zhi. 2017 May 4;55(5):349-354. doi: 10.3760/cma.j.issn.0578-1310.2017.05.008. Zhonghua Er Ke Za Zhi. 2017. PMID: 28482385 Clinical Trial. Chinese. - Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double-blind, randomized, and controlled trial.
Spapen H, Diltoer M, Van Malderen C, Opdenacker G, Suys E, Huyghens L. Spapen H, et al. Clin Nutr. 2001 Aug;20(4):301-5. doi: 10.1054/clnu.2001.0399. Clin Nutr. 2001. PMID: 11478826 Clinical Trial. - The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials.
Lewis K, Alqahtani Z, Mcintyre L, Almenawer S, Alshamsi F, Rhodes A, Evans L, Angus DC, Alhazzani W. Lewis K, et al. Crit Care. 2016 Aug 15;20(1):259. doi: 10.1186/s13054-016-1441-z. Crit Care. 2016. PMID: 27527069 Free PMC article. Review. - Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.
McFarland LV. McFarland LV. World J Gastroenterol. 2010 May 14;16(18):2202-22. doi: 10.3748/wjg.v16.i18.2202. World J Gastroenterol. 2010. PMID: 20458757 Free PMC article. Review.
Cited by
- Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis.
Manzanares W, Lemieux M, Langlois PL, Wischmeyer PE. Manzanares W, et al. Crit Care. 2016 Aug 19;19:262. doi: 10.1186/s13054-016-1434-y. Crit Care. 2016. PMID: 27538711 Free PMC article. Review. - Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives.
Buts JP. Buts JP. Dig Dis Sci. 2009 Jan;54(1):15-8. doi: 10.1007/s10620-008-0322-y. Epub 2008 Jun 5. Dig Dis Sci. 2009. PMID: 18528758 Review. No abstract available. - Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review.
Moré MI, Swidsinski A. Moré MI, et al. Clin Exp Gastroenterol. 2015 Aug 14;8:237-55. doi: 10.2147/CEG.S85574. eCollection 2015. Clin Exp Gastroenterol. 2015. PMID: 26316791 Free PMC article. Review. - Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition.
Schneider SM, Girard-Pipau F, Filippi J, Hebuterne X, Moyse D, Hinojosa GC, Pompei A, Rampal P. Schneider SM, et al. World J Gastroenterol. 2005 Oct 21;11(39):6165-9. doi: 10.3748/wjg.v11.i39.6165. World J Gastroenterol. 2005. PMID: 16273644 Free PMC article. Clinical Trial. - PRKN/parkin-mediated mitophagy is induced by the probiotics Saccharomyces boulardii and Lactococcus lactis.
Hawrysh PJ, Gao J, Tan S, Oh A, Nodwell J, Tompkins TA, McQuibban GA. Hawrysh PJ, et al. Autophagy. 2023 Jul;19(7):2094-2110. doi: 10.1080/15548627.2023.2172873. Epub 2023 Feb 5. Autophagy. 2023. PMID: 36708254 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical